Point72 Asset Management L.P. Buys Shares of 247,089 Autolus Therapeutics plc (NASDAQ:AUTL)

Point72 Asset Management L.P. bought a new position in Autolus Therapeutics plc (NASDAQ:AUTL - Free Report) during the 4th quarter, according to its most recent filing with the SEC. The institutional investor bought 247,089 shares of the company's stock, valued at approximately $581,000. Point72 Asset Management L.P. owned approximately 0.09% of Autolus Therapeutics at the end of the most recent reporting period.

A number of other hedge funds have also recently made changes to their positions in the company. Arkadios Wealth Advisors bought a new position in Autolus Therapeutics in the 4th quarter worth about $47,000. Dumont & Blake Investment Advisors LLC bought a new stake in shares of Autolus Therapeutics during the 4th quarter worth $35,000. Aubrey Capital Management Ltd bought a new position in Autolus Therapeutics in the fourth quarter valued at $199,000. Handelsbanken Fonder AB lifted its stake in Autolus Therapeutics by 30.9% during the fourth quarter. Handelsbanken Fonder AB now owns 73,300 shares of the company's stock worth $172,000 after purchasing an additional 17,300 shares during the last quarter. Finally, HealthInvest Partners AB lifted its stake in Autolus Therapeutics by 8.4% during the fourth quarter. HealthInvest Partners AB now owns 479,644 shares of the company's stock worth $1,060,000 after purchasing an additional 37,221 shares during the last quarter. 72.83% of the stock is currently owned by hedge funds and other institutional investors.

Autolus Therapeutics Trading Up 0.7%

NASDAQ AUTL traded up $0.01 on Monday, hitting $1.54. The company's stock had a trading volume of 1,152,692 shares, compared to its average volume of 1,492,130. The firm has a market cap of $409.86 million, a P/E ratio of -1.27 and a beta of 1.77. Autolus Therapeutics plc has a 52-week low of $1.11 and a 52-week high of $5.00. The company's 50-day simple moving average is $1.42 and its 200 day simple moving average is $2.06.

Autolus Therapeutics (NASDAQ:AUTL - Get Free Report) last announced its quarterly earnings results on Thursday, May 8th. The company reported ($0.26) EPS for the quarter, missing analysts' consensus estimates of ($0.24) by ($0.02). The company had revenue of $8.98 million during the quarter, compared to the consensus estimate of $1.59 million. On average, research analysts forecast that Autolus Therapeutics plc will post -0.94 EPS for the current fiscal year.

Wall Street Analyst Weigh In

AUTL has been the topic of a number of research reports. Truist Financial decreased their price objective on Autolus Therapeutics from $11.00 to $10.00 and set a "buy" rating on the stock in a report on Tuesday, April 1st. Needham & Company LLC reissued a "buy" rating and issued a $10.00 target price on shares of Autolus Therapeutics in a research note on Thursday, April 10th. Finally, Wells Fargo & Company reduced their price target on Autolus Therapeutics from $8.00 to $6.00 and set an "overweight" rating on the stock in a research report on Friday, March 21st. Six equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company currently has an average rating of "Buy" and an average price target of $9.32.

Autolus Therapeutics Company Profile

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.